All News
Filter News
Found 808,490 articles
-
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
8/28/2023
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Jeff Caravella as Chief Financial Officer.
-
Zylox-Tonbridge Reveals 2023 Interim Financial Results: Revenue Surges 50.7% YOY to 230 Million Yuan, Gross Profit Climbs to 171 Million Yuan
8/28/2023
On August 23rd, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. released its financial results for the first half of 2023.
-
Genelux Corporation Announces New Chief Financial Officer
8/28/2023
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.
-
Rhythm Pharmaceuticals to Present at Investor Conferences in September 2023
8/28/2023
Rhythm Pharmaceuticals, Inc. announced that Company management will present at three investor conferences in September:
-
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress
8/28/2023
Innovative vaccine company Recbio announced its latest progress and interim results for 2023.
-
Kymera Therapeutics to Participate in Upcoming September 2023 Investor Conferences
8/28/2023
Kymera Therapeutics, Inc. announced that the Company’s management team will attend and participate in presentations at the following upcoming investor events:
-
AlloVir to Present at Upcoming September 2023 Investor Conferences
8/28/2023
AlloVir, Inc. announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET H.C.
-
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
8/28/2023
ContraFect Corporation announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
-
Cybin to Acquire Small Pharma Inc.
8/28/2023
All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -
-
FDA Rejects Bulk Compounding For Ephedrine Sulfate
8/28/2023
Nexus Pharmaceuticals LLC announced that the U.S. Food and Drug Administration (FDA) issued a notice in the Federal Register that ephedrine sulfate should not be bulked by compounding facilities.
-
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
8/28/2023
Bristol Myers Squibb (NYSE: BMY) today announced new long-term follow-up results from two Phase 3 studies evaluating CAMZYOS® (mavacamten), a first-in-class cardiac myosin inhibitor, in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
-
New Hope for Treating Acne Keloidalis Nuchae (AKN) Revealed in Recent Study
8/28/2023
Dr. U Hair and Skin Clinic announces a recent research report has illuminated a potential breakthrough in treating Acne Keloidalis Nuchae (AKN), a chronic and burdensome condition.
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
8/28/2023
The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.
-
Empyrean, MagCorp, and MetOx Announce Strategic Collaboration Agreement on the Scale-up of Novel Technology for Radiation Therapy and Cancer Treatment
8/28/2023
Empyrean Medical Systems, Inc. ("Empyrean"), MagCorp Inc. ("MagCorp"), and MetOx Technologies, Inc. ("MetOx") today announced a strategic collaboration agreement to accelerate the large-scale development of novel technology that will enable commercial production of next generation, state-of-the-art radiation therapy technology for cancer treatment.
-
Soterix Medical announces Phase-2 trial to test at-home tDCS paired with cognitive training as a therapeutic option for long COVID
8/28/2023
Soterix Medical Inc. announces the launch of a Phase-2 clinical trial that will evaluate the combination of REMOTE-tDCS and a brain training program for the treatment of long COVID.
-
LIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial
8/28/2023
LIB Therapeutics Inc., a clinical-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor medicines for patients at very high and high risk of cardiovascular disease (“CVD”) requiring additional reductions in LDL- cholesterol (“LDL-C” or “LDL”), in patients on maximally tolerated statins and other oral lipid lowering agents, announced the results of the LIBerate-HeFH trial.
-
Cantex Pharmaceuticals Announces Initiation of an Investigator-Initiated Phase 2 Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
8/28/2023
Cantex Pharmaceuticals, Inc. announced today the initiation of a Phase 2 clinical trial to assess the safety and effectiveness of Cantex's azeliragon combined with stereotactic radiosurgery in patients with brain metastases.
-
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
8/28/2023
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”) today announced preclinical data demonstrating the Company’s lead drug candidate GT-02287 significantly decreased Parkinson’s disease (PD)-associated pathology and improved motor dysfunction in two different preclinical models of Parkinson’s disease.
-
XtalPi Inc. Unveils "XtalPi Intelligent Automation" and Announces New Automation Facility in Shanghai
8/28/2023
XtalPi Inc., a leading technology platform company renowned for melding physics-based computation, artificial intelligence, and robotics to advance the discovery and evolution of groundbreaking medicines and innovative materials, unveiled its newest brand, XtalPi Intelligent Automation, at the inaugural Intelligent Automation Forum on August 25th, 2023, in Shanghai, China.
-
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
8/28/2023
Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.